Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Parving, H-H, Brenner, BM, McMurray, JJV, de Zeeuw, D, Haffner, SM, Solomon, SD, Chaturvedi, N, Persson, F, Nicolaides, M, Richard, A, Xiang, Z, Armbrecht, J, Pfeffer, MA & ALTITUDE Investigators 2012, 'Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)' Journal of the Renin-Angiotensin-Aldosterone System, bind 13, nr. 3, s. 387-93. https://doi.org/10.1177/1470320311434818

APA

CBE

Parving H-H, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Nicolaides M, Richard A, Xiang Z, Armbrecht J, Pfeffer MA, ALTITUDE Investigators. 2012. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). Journal of the Renin-Angiotensin-Aldosterone System. 13(3):387-93. https://doi.org/10.1177/1470320311434818

MLA

Vancouver

Author

Parving, Hans-Henrik ; Brenner, Barry M ; McMurray, John J V ; de Zeeuw, Dick ; Haffner, Steven M ; Solomon, Scott D ; Chaturvedi, Nish ; Persson, Frederik ; Nicolaides, Maria ; Richard, Alexia ; Xiang, Zhihua ; Armbrecht, Juergen ; Pfeffer, Marc A ; ALTITUDE Investigators. / Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). I: Journal of the Renin-Angiotensin-Aldosterone System. 2012 ; Bind 13, Nr. 3. s. 387-93.

Bibtex

@article{cb40efc05ce242f0bb0bbf8d18214a3b,
title = "Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)",
abstract = "Patients with type 2 diabetes are at enhanced risk for macro- and microvascular complications. Albuminuria and/or reduced kidney function further enhances the vascular risk. We initiated the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). Aliskiren, a novel direct renin inhibitor, which lowers plasma renin activity, may thereby provide greater cardio-renal protection compared with angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) alone.",
author = "Hans-Henrik Parving and Brenner, {Barry M} and McMurray, {John J V} and {de Zeeuw}, Dick and Haffner, {Steven M} and Solomon, {Scott D} and Nish Chaturvedi and Frederik Persson and Maria Nicolaides and Alexia Richard and Zhihua Xiang and Juergen Armbrecht and Pfeffer, {Marc A} and {ALTITUDE Investigators}",
year = "2012",
doi = "10.1177/1470320311434818",
language = "English",
volume = "13",
pages = "387--93",
journal = "JRAAS - Journal of the Renin-Angiotensin-Aldosterone System",
issn = "1470-3203",
publisher = "Sage Science Press (UK)",
number = "3",

}

RIS

TY - JOUR

T1 - Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

AU - Parving, Hans-Henrik

AU - Brenner, Barry M

AU - McMurray, John J V

AU - de Zeeuw, Dick

AU - Haffner, Steven M

AU - Solomon, Scott D

AU - Chaturvedi, Nish

AU - Persson, Frederik

AU - Nicolaides, Maria

AU - Richard, Alexia

AU - Xiang, Zhihua

AU - Armbrecht, Juergen

AU - Pfeffer, Marc A

AU - ALTITUDE Investigators

PY - 2012

Y1 - 2012

N2 - Patients with type 2 diabetes are at enhanced risk for macro- and microvascular complications. Albuminuria and/or reduced kidney function further enhances the vascular risk. We initiated the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). Aliskiren, a novel direct renin inhibitor, which lowers plasma renin activity, may thereby provide greater cardio-renal protection compared with angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) alone.

AB - Patients with type 2 diabetes are at enhanced risk for macro- and microvascular complications. Albuminuria and/or reduced kidney function further enhances the vascular risk. We initiated the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). Aliskiren, a novel direct renin inhibitor, which lowers plasma renin activity, may thereby provide greater cardio-renal protection compared with angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) alone.

U2 - 10.1177/1470320311434818

DO - 10.1177/1470320311434818

M3 - Journal article

VL - 13

SP - 387

EP - 393

JO - JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

JF - JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

SN - 1470-3203

IS - 3

ER -

ID: 36594289